Monthly

Blossom keeps close track of new psychedelic research to keep you up-to-date. In cooperation with Psychedelic Alpha, we publish a monthly overview that recaps the latest research in one article. All papers that didn’t make the cut are featured in our handy link overviews.

In November, we got results of COMPASS Pathways Phase II trial, antidepressants were found to weaken the effects of psilocybin while ketanserin has the potential to stop an LSD trip.
This is all the other psychedelic research that came out in November 2022. These papers don't (yet) have their own page in our database.
In October, natural language processing (NLP) was used to successfully predict clinical outcomes using data from a trial exploring psilocybin on treatment-resistant depression (TRD). The first real-world study assessing esketamine for TRD yielded positive results, while new evidence suggests people who microdose may build a tolerance which needs to be taken in future trials.
This is all the other psychedelic research that came out in October 2022 that we haven't added to our main database.
Over the past month, we gained some positive insights into the effectiveness ketamine in the real-world data. The official results of the first trial using LSD to treat generalized anxiety disorder were published and researchers continue to learn more about what psychedelics are doing in the brain.
This is all the other psychedelic research that came out in September 2022 that we haven't added to our main database.
While many of us had the chance to enjoy a vacation this summer, psychedelic researchers continued their hard work. They continued to unearth more about the therapeutic potential of these compounds. A big real-world study on at-home ketamine therapy finds promising results. At the same time, psilocybin was tested for alcoholism in a double-blind, placebo-controlled study design for the first time.
This is all the other psychedelic research that came out in August 2022 that we haven't added to our main database.
Summer is officially here and psychedelic researchers are continuing their efforts to turn these medicines into viable therapy options. Despite relatively few clinical trials being published over the month of June, we're continuing to learn more about the effects of psychedelics through the reanalysis of existing datasets and surveys.
This is all the other psychedelic research that came out in July 2022 that we haven't added to our main database.

Research Briefings

At Blossom, we start our day by gathering the latest psychedelic research. Our inbox receives the latest from PubMed, psyarxiv, Google Scholar, and the many other sources where new research is being published.

In the monthly recap, now running for over 2 years, we bring together this deluge of information in an easy to understand format.

All papers that haven’t made the cut are still archived in our link overviews.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account